According to the analysis for biologics in a large number of literature (294, 295), compared with traditional antirheumatic drugs (MTX), glucocorticoids, corticosteroids, biologic disease-modifying antirheumatic drugs (such as TNF-α inhibitors) seem to improve the symptoms and signs of RA patients more quickly, without producing very serious adverse effects, so these drugs have a relative safety profile for RA in the short term. Here, TNF is linked to rheumatoid arthritis.